AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24136281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm thick soft splint
Number of subjects: 25
Study 24136281 — intervention group
Group type: COMPARATOR
Intervention: 2 mm thick resin stability splint
Number of subjects: 25
Study 24136281 — intervention group
Group type: COMPARATOR
Intervention: 4 mm thick resin stability splint
Number of subjects: 25
Study 24136281 — intervention group
Group type: COMPARATOR
Intervention: buccolingual mock splint
Number of subjects: 25
Study 24136281 — intervention group
Group type: COMPARATOR
Intervention: no splint
Number of subjects: 25
Study 21606974 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg A3309
Number of subjects: 190
Study 21606974 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg A3309
Number of subjects: 190
Study 21606974 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg A3309
Number of subjects: 190
Study 21606974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 19388900 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 1%
Number of subjects: 18
Study 19388900 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 2%
Number of subjects: 18
Study 19388900 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study 22878195 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of Pueraria flower extract (PFE)
Number of subjects: 81
Study 22878195 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of Pueraria flower extract (PFE)
Number of subjects: 81
Study 22878195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 16786177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling
Number of subjects: 49
Study 16786177 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy without ILM peeling
Number of subjects: 49
Study 16786177 — intervention group
Group type: COMPARATOR
Intervention: Comparison of visual acuity change between Group I and Group II
Number of subjects: 49
Study 12654763 — intervention group
Group type: EXPERIMENTAL
Intervention: telithromycin 800 mg once daily
Number of subjects: 3935
Study 9793807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 micrograms) without prior i.v. fluid
Number of subjects: 30
Study 9793807 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl (25 micrograms) with prior i.v. fluid (500 ml of lactated Ringer's solution)
Number of subjects: 30
Study 9793807 — intervention group
Group type: COMPARATOR
Intervention: Fluid infusion (500 ml of lactated Ringer's solution)
Number of subjects: 30
Study 7648764 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810 (20 mg once daily for 7 days)
Number of subjects: 15
Study 7648764 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily for 7 days)
Number of subjects: 15
Study 7648764 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810
Number of subjects: 15
Study 7648764 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 15
Study 7648764 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810 and Omeprazole
Number of subjects: 15
Study 2771866 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide single bolus injection (150 mg) over 5 min
Number of subjects: 8
Study 2771866 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide infusion (28.2 mg/h to steady state)
Number of subjects: 8
Study 2771866 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide single bolus injection (150 mg)
Number of subjects: 8
Study 2771866 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (both methods)
Number of subjects: 8
Study 1272721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate self-disclosure
Number of subjects: 65
Study 1272721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintimate self-disclosure
Number of subjects: 65
Study 1272721 — intervention group
Group type: COMPARATOR
Intervention: Control (no disclosure)
Number of subjects: 65
Study 12078386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3 g vitamin C
Number of subjects: 40
Study 12078386 — intervention group
Group type: COMPARATOR
Intervention: 100 ml 0.9% saline solution (placebo)
Number of subjects: 40
Study 29389836 — intervention group
Group type: COMPARATOR
Intervention: CON/ECC (conventional concentric/eccentric strength training)
Number of subjects: 37
Study 27212612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis before skin incision (A)
Number of subjects: 279
Study 27212612 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis after umbilical cord clamping (C)
Number of subjects: 279
Study 24771017 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Choices (PC) intervention
Number of subjects: 102
Study 24771017 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive standard of care (C-SoC)
Number of subjects: 102
Study 23095627 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary anastomosis (PA) with diverting ileostomy
Number of subjects: 62
Study 23095627 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure (HP)
Number of subjects: 62
Study 20166406 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH Spectrum/XenoIII (TS) restoration group
Number of subjects: 32
Study 20166406 — intervention group
Group type: COMPARATOR
Intervention: Synergy Compact/One Coat (SC) restoration group
Number of subjects: 32
Study 18586991 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions training (N=40)
Number of subjects: 78
Study 18586991 — intervention group
Group type: COMPARATOR
Intervention: No implementation intentions training (N=38)
Number of subjects: 78
Study 16375216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth dissolving tablets (Nimulid-MD)
Number of subjects: 12
Study 16375216 — intervention group
Group type: COMPARATOR
Intervention: Nimulid suspension
Number of subjects: 12
Study 16375216 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablets
Number of subjects: 12
Study 16375216 — intervention group
Group type: COMPARATOR
Intervention: Mouth dissolving tablets
Number of subjects: 12
Study 16375216 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 12
Study 12194075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein Meniscus Time (FMT)
Number of subjects: 62
Study 12194075 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer's Test (ST)
Number of subjects: 62
Study 12194075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear Break Up Time (TBUT)
Number of subjects: 62
Study 12194075 — intervention group
Group type: COMPARATOR
Intervention: Control Group (15 subjects tested for reproducibility of FMT)
Number of subjects: 62
Study 10206567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral techniques (16-hour, 8-week class)
Number of subjects: 0
Study 10206567 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment (home-study manual)
Number of subjects: 0
Study 7628887 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 micrograms/kg dofetilide
Number of subjects: 16
Study 7628887 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms/kg dofetilide
Number of subjects: 16
Study 7628887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7628887 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 16
Study 7628887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (8 and 12 micrograms/kg)
Number of subjects: 16
Study 2930443 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured research-based marital therapy
Number of subjects: 30
Study 2930443 — intervention group
Group type: COMPARATOR
Intervention: Clinically flexible marital therapy
Number of subjects: 30
Study 69192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study 69192 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule in air (Control)
Number of subjects: 0
Study 31238828 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined risk of depression (1-SD increase)
Number of subjects: 6021
Study 28441365 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tube
Number of subjects: 66
Study 28441365 — intervention group
Group type: EXPERIMENTAL
Intervention: Beschitin‐F
Number of subjects: 66
Study 28441365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel1‐Ag
Number of subjects: 66
Study 25311148 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST
Number of subjects: 525
Study 25311148 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST-Lite
Number of subjects: 525
Study 23905228 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence
Number of subjects: 130
Study 21742301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional methotrexate infiltration (single dose)
Number of subjects: 25
Study 21742301 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 25
Study 19738565 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic therapy (TcMT), 10 sessions, bitemporal method, modulation frequency 1-10 Hz
Number of subjects: 80
Study 19738565 — intervention group
Group type: COMPARATOR
Intervention: Placebo sessions of TcMT with magnetic power supply switched off
Number of subjects: 80
Study 16320011 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter‐mediated femoral nerve block with 1% prilocaine (40 ml) and post‐operatively 0.2% ropivacaine (30 ml) 6 hourly
Number of subjects: 100
Study 16320011 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metamizol (1 g) and oral tilidine (100 mg) + naloxone (8 mg), with reduced doses for patients aged 90 years or more
Number of subjects: 100
Study 14571608 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Rhodiolae (CR) administered 4 g daily for 7-10 days before and 5-7 days after the operation
Number of subjects: 76
Study 14571608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 76
Study 10964859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 30
Study 10964859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8985019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg i.v. weekly with forced hydration during radiotherapy (CM group)
Number of subjects: 83
Study 8985019 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (RT group)
Number of subjects: 83
Study 1478406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine controlled-release suppository 1 g once daily
Number of subjects: 50
Study 1478406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6141898 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 93479 (20, 40, 60, and 80 mg)
Number of subjects: 0
Study 6141898 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 93479 (80 mg)
Number of subjects: 0
Study 6141898 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 93479
Number of subjects: 0
Study 6141898 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (300 mg)
Number of subjects: 0
Study 30669147 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcimimetic cinacalcet
Number of subjects: 1494
Study 30669147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1494
Study 29397627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcystic biliary drainage
Number of subjects: 106
Study 29397627 — intervention group
Group type: COMPARATOR
Intervention: Nasobiliary drainage
Number of subjects: 106
Study 27273941 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐chTNT and PMCT
Number of subjects: 96
Study 27273941 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with docetaxel and cisplatin and three‐dimensional conformal radiotherapy
Number of subjects: 96
Study 25239625 — intervention group
Group type: EXPERIMENTAL
Intervention: Email intervention (personalized emails reminding of legal requirement)
Number of subjects: 190
Study 25239625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no email intervention)
Number of subjects: 190
Study 23259231 — intervention group
Group type: EXPERIMENTAL
Intervention: Group voice and singing intervention (60 minutes, once a week for 20 weeks)
Number of subjects: 10
Study 21144025 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month behavioral weight loss intervention
Number of subjects: 320
Study 21144025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 18072836 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Number of subjects: 258
Study 18072836 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Number of subjects: 258
Study 15449047 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I administration (3.7 GBq)
Number of subjects: 30
Study 15449047 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro irradiation at doses of 0.5, 1 and 2 Gy
Number of subjects: 30
Study 15449047 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study 12403316 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP10deltaPK vaccine
Number of subjects: 0
Study 12403316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10235427 — intervention group
Group type: EXPERIMENTAL
Intervention: Napsagatran 5 mg/h
Number of subjects: 105
Study 10235427 — intervention group
Group type: EXPERIMENTAL
Intervention: Napsagatran 9 mg/h
Number of subjects: 105
Study 10235427 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 105
Study 10235427 — intervention group
Group type: EXPERIMENTAL
Intervention: Napsagatran 5 mg/h and 9 mg/h
Number of subjects: 105
Study 8917236 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 22505
Study 1887351 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg gentamicin
Number of subjects: 89
Study 1887351 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg gentamicin
Number of subjects: 89
Study 1887351 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg gentamicin
Number of subjects: 89
Study 6651314 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methoxsalen and total body irradiation
Number of subjects: 23
Study 6651314 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical applications of methoxsalen or oral methoxsalen combined with local irradiation of the scalp
Number of subjects: 23
Study 6651314 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment (psoralens and UV‐A)
Number of subjects: 23
Study 6651314 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with long‐lasting alopecia
Number of subjects: 23
Study 29245022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case‐managed program combined with contingency management (NCM + CM)
Number of subjects: 451
Study 29245022 — intervention group
Group type: COMPARATOR
Intervention: Standard education plus contingency management (SE + CM)
Number of subjects: 451
Study 28320258 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC) in women
Number of subjects: 20
Study 28320258 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise (CONC) in men
Number of subjects: 20
Study 28320258 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC) in men
Number of subjects: 20
Study 26184556 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammation
Number of subjects: 886
Study 26184556 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammation
Number of subjects: 886
Study 23020819 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-containing powder (daily dose of minimum 1 billion colony-forming units of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12®), n=114
Number of subjects: 231
Study 23020819 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=117
Number of subjects: 231
Study 21078150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in women
Number of subjects: 1978
Study 21078150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in women after 12 months
Number of subjects: 1978
Study 21078150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in men
Number of subjects: 1978
Study 21078150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in men after 12 months
Number of subjects: 1978
Study 18186151 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal screening test offer
Number of subjects: 59
Study 16356192 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 57
Study 15311008 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (400 mg calcium twice daily)
Number of subjects: 18
Study 15311008 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (20 mEq twice daily)
Number of subjects: 18
Study 15311008 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate and potassium citrate (at same doses)
Number of subjects: 18
Study 15311008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10914793 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR+ABB (cellulose membrane + bovine-derived anorganic bone)
Number of subjects: 14
Study 10914793 — intervention group
Group type: COMPARATOR
Intervention: GTR (membrane alone)
Number of subjects: 14
Study 9328950 — intervention group
Group type: EXPERIMENTAL
Intervention: High alkali dialysate (HA; lactate 40 mmol/liter)
Number of subjects: 200
Study 9328950 — intervention group
Group type: COMPARATOR
Intervention: Low alkali dialysate (LA; lactate 35 mmol/liter)
Number of subjects: 200
Study 9328950 — intervention group
Group type: EXPERIMENTAL
Intervention: High alkali dialysate (HA)
Number of subjects: 200
Study 9328950 — intervention group
Group type: COMPARATOR
Intervention: Low alkali dialysate (LA)
Number of subjects: 200
Study 8403647 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft (PT)
Number of subjects: 55
Study 8403647 — intervention group
Group type: COMPARATOR
Intervention: Leeds-Keio graft (LK)
Number of subjects: 55
Study 3519242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20
Study 3519242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3277579 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 76
Study 3277579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 29743101 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative, algorithm-driven hemodynamic therapy based on individualized fluid status and cardiac output optimization using pulse-pressure variation (PPV) and pulse-contour analysis (ProAQT© device).
Number of subjects: 380
Study 29743101 — intervention group
Group type: COMPARATOR
Intervention: Standard local care based on established basic hemodynamic treatment.
Number of subjects: 380
Study 29743101 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative, algorithm-driven hemodynamic therapy.
Number of subjects: 380
Study 27413130 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D 600 IU/d
Number of subjects: 257
Study 27413130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3750 IU/d
Number of subjects: 257
Study 24712855 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused treatment
Number of subjects: 100
Study 24712855 — intervention group
Group type: COMPARATOR
Intervention: Conjoint family‐based treatment
Number of subjects: 100
Study 22993169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance (OA) therapy
Number of subjects: 51
Study 22993169 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurement of OA compliance
Number of subjects: 51
Study 22993169 — intervention group
Group type: COMPARATOR
Intervention: Self-reported OA compliance data
Number of subjects: 51
Study 20498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy
Number of subjects: 465
Study 20498212 — intervention group
Group type: COMPARATOR
Intervention: Initial monotherapy
Number of subjects: 465
Study 20498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 465
Study 20498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix model
Number of subjects: 465
Study 19086875 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) at doses ranging from 50 to 400 mg/day
Number of subjects: 0
Study 19086875 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS)
Number of subjects: 0
Study 16360211 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% prednisolone drops
Number of subjects: 41
Study 16360211 — intervention group
Group type: COMPARATOR
Intervention: 0.1% hyaluronic acid drops
Number of subjects: 41
Study 16360211 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 41
Study 15325501 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with nucleotides added
Number of subjects: 12
Study 15325501 — intervention group
Group type: COMPARATOR
Intervention: Infant formula without nucleotides
Number of subjects: 12
Study 11102741 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 6
Study 11102741 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 6
Study 11102741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9057957 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan potassium
Number of subjects: 29
Study 9057957 — intervention group
Group type: COMPARATOR
Intervention: felodipine
Number of subjects: 29
Study 9057957 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan potassium (diabetic group)
Number of subjects: 29
Study 9057957 — intervention group
Group type: COMPARATOR
Intervention: felodipine (diabetic group)
Number of subjects: 29
Study 9057957 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan potassium (non-diabetic group)
Number of subjects: 29
Study 9057957 — intervention group
Group type: COMPARATOR
Intervention: felodipine (non-diabetic group)
Number of subjects: 29